Despite the complexity, significant progress has been made, with several anthelminthic vaccines advancing through clinical development for schistosomiasis, including a candidate targeting Schistosoma mansoni tetraspanin 2 (Sm-TSP-2) protein [4, 5]. This evidence concerns the gene THBS2 and schistosomiasis.